OLYMPUSby New Odyssey
Menu
SEC registrant · CIK 0001325879

AVEO PHARMACEUTICALS, INC.

AVEO PHARMACEUTICALS, INC. (CIK 0001325879, EIN 04-3581650) reported revenue of $42.3 million ($42,295,000) for FY2021 (2021-01-01 to 2021-12-31) and net income of -$53.34 million (-$53,342,000) for FY2021 (2021-01-01 to 2021-12-31), as filed in its 10-K filed 2022-03-14 (accession 0001628280-22-006093).

Figures are as filed with the SEC in XBRL, in whole US dollars unless stated, for the company's own fiscal years (fiscal year ends December 31).

Data as of Oct 21, 2026 (Olympus publication) · Markdown version

  • Values are as filed by the company in its 10-K and 10-Q XBRL data. When a later filing restates a value, the latest filed value is shown and the first reported value is noted.

Identifiers

As published in the company's EDGAR submissions record.

IdentifierValue
CIK0001325879
EIN04-3581650
SIC industry code2834 Pharmaceutical Preparations
Fiscal year endDecember 31
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
Olympus entity IDorg_2x1t23vdxk4jbx03knxvdz5zgh
  • The EIN is the one the filer gave to EDGAR. The SEC does not verify it; Olympus checks only that it has nine digits and a prefix the IRS assigns.

Latest annual financial metrics

The latest annual value of each standardised metric, with the filing it was taken from.

MetricValueFiscal periodPeriodFormFiledAccession numberXBRL concept
Revenue$42,295,000FY20212021-01-01 to 2021-12-3110-K2022-03-140001628280-22-006093RevenueFromContractWithCustomerExcludingAssessedTax
Net income-$53,342,000FY20212021-01-01 to 2021-12-3110-K2022-03-140001628280-22-006093NetIncomeLoss
Total assets$105,341,000FY2021as of 2021-12-3110-K2022-03-140001628280-22-006093Assets
Total liabilities$59,471,000FY2021as of 2021-12-3110-K2022-03-140001628280-22-006093Liabilities
Stockholders' equity$45,870,000FY2021as of 2021-12-3110-K2022-03-140001628280-22-006093StockholdersEquity
Operating cash flow-$57,257,000FY20212021-01-01 to 2021-12-3110-K2022-03-140001628280-22-006093NetCashProvidedByUsedInOperatingActivities
Diluted earnings per share-$1.63 per shareFY20212021-01-01 to 2021-12-3110-K2022-03-140001628280-22-006093EarningsPerShareDiluted
Shares outstanding34,474,710 sharesFY2021as of 2022-03-0910-K2022-03-140001628280-22-006093EntityCommonStockSharesOutstanding
  • Accession numbers link to the filing's index on SEC EDGAR.

Revenue and net income history

Every annual revenue and net income value served for fiscal years 2012-2021, newest first, each with its filing.

MetricFiscal periodPeriodValueFormFiledAccession number
RevenueFY20212021-01-01 to 2021-12-31$42,295,00010-K2022-03-140001628280-22-006093
RevenueFY20202020-01-01 to 2020-12-31$6,019,00010-K2022-03-140001628280-22-006093
RevenueFY20192019-01-01 to 2019-12-31$28,795,00010-K2022-03-140001628280-22-006093
RevenueFY20182018-01-01 to 2018-12-31$5,409,00010-K2021-03-160001564590-21-013607
RevenueFY20172017-01-01 to 2017-12-31$7,579,00010-K2018-03-130001564590-18-005386
RevenueFY20162016-01-01 to 2016-12-31$2,515,00010-K2018-03-130001564590-18-005386
RevenueFY20152015-01-01 to 2015-12-31$19,024,00010-K2018-03-130001564590-18-005386
RevenueFY20142014-01-01 to 2014-12-31$18,123,00010-K2017-03-220001564590-17-005015
RevenueFY20132013-01-01 to 2013-12-31$1,293,00010-K2016-03-150001564590-16-014772
RevenueFY20122012-01-01 to 2012-12-31$19,286,00010-K2015-03-060001193125-15-079651
Net incomeFY20212021-01-01 to 2021-12-31-$53,342,00010-K2022-03-140001628280-22-006093
Net incomeFY20202020-01-01 to 2020-12-31-$35,584,00010-K2022-03-140001628280-22-006093
Net incomeFY20192019-01-01 to 2019-12-31$9,388,00010-K2022-03-140001628280-22-006093
Net incomeFY20182018-01-01 to 2018-12-31-$5,329,00010-K2021-03-160001564590-21-013607
Net incomeFY20172017-01-01 to 2017-12-31-$65,025,00010-K2020-03-160001564590-20-011145
Net incomeFY20162016-01-01 to 2016-12-31-$26,887,00010-K2019-03-140001564590-19-007804
Net incomeFY20152015-01-01 to 2015-12-31-$15,001,00010-K2018-03-130001564590-18-005386
Net incomeFY20142014-01-01 to 2014-12-31-$52,739,00010-K2017-03-220001564590-17-005015
Net incomeFY20132013-01-01 to 2013-12-31-$107,029,00010-K2016-03-150001564590-16-014772
Net incomeFY20122012-01-01 to 2012-12-31-$114,394,00010-K2015-03-060001193125-15-079651

Recent 10-K and 10-Q filings

The 12 most recent 10-K, 10-Q and amendment filings in EDGAR, newest first.

FormFiledPeriod of reportAccession numberDocument
10-Q2022-11-072022-09-300001628280-22-028635aveo-20220930.htm
10-Q2022-08-042022-06-300001628280-22-021160aveo-20220630.htm
10-Q2022-05-052022-03-310001628280-22-012410aveo-20220331.htm
10-K2022-03-142021-12-310001628280-22-006093aveo-20211231.htm
10-Q2021-11-082021-09-300001628280-21-022223aveo-20210930.htm
10-Q2021-08-052021-06-300001564590-21-041703aveo-10q_20210630.htm
10-Q2021-05-102021-03-310001564590-21-026089aveo-10q_20210331.htm
10-K2021-03-162020-12-310001564590-21-013607aveo-10k_20201231.htm
10-Q2020-11-092020-09-300001564590-20-052556aveo-10q_20200930.htm
10-Q2020-08-102020-06-300001564590-20-038899aveo-10q_20200630.htm
10-Q2020-04-302020-03-310001564590-20-019921aveo-10q_20200331.htm
10-K2020-03-162019-12-310001564590-20-011145aveo-10k_20191231.htm

Identifier registry

The company's identifiers in the Olympus identifier registry, each with how it was linked and its source.

SchemeValueHow linkedSourcePublished
SEC Central Index Key (CIK) · OLY-US-SEC-CIK0001325879published by the sourcedata.sec.gov/submissions/CIK0001325879.json2026-10-21
Employer Identification Number (EIN) · US-EIN04-3581650published by the sourcedata.sec.gov/submissions/CIK0001325879.json2026-10-21

Former names

NameFromTo
AVEO PHARMACEUTICALS INC2005-04-272020-04-23

Sources

  • EDGAR submissions (nightly bulk archive) (company profile and filings) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:f7d2a4f18cb91aae, source date 2026-10-20. https://data.sec.gov/submissions/CIK0001325879.json
  • EDGAR XBRL company facts (nightly bulk archive) (financial metrics) — U.S. Securities and Exchange Commission. EDGAR snapshot sha256:01e4045aa34d7224, source date 2026-10-20. https://data.sec.gov/api/xbrl/companyfacts/CIK0001325879.json
  • Published by Olympus on Oct 21, 2026.
  • Source data: U.S. Securities and Exchange Commission (EDGAR). Values are as filed by the registrant; Olympus does not audit or adjust them.
  • Olympus is not affiliated with or endorsed by the U.S. Securities and Exchange Commission.

Get this data from the API

The same figures, with provenance on every value, from the API (free API key, reference) or from an AI agent through the Olympus MCP server.

curl
curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001325879" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001325879/financials" -H "X-API-Key: $OLYMPUS_API_KEY"

curl -s "https://api.olympus.new-odyssey.com/v1/sec/companies/0001325879/filings?limit=12" -H "X-API-Key: $OLYMPUS_API_KEY"
MCP tool call
get_sec_company_financials {"cik":"1325879"}

On SEC EDGAR

About this data